Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

It's one of many changes Bayer CEO Bill Anderson has made. Still, the company's stock price this year has struggled.

Bayer is looking to accelerate its patient ... related side effects to be detected much earlier. The German pharmaceutical company has tied up with professional services firm Genpact for the ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals ...

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

Notably, the company warned that 2025 will be weaker ... Sales of glyphosate-based herbicides declined by 19% YoY. Meanwhile, Bayer's Pharmaceutical division has delivered mixed performance.